Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aliskiren Dose-Ranging Study in Essential Hypertension
NCT00260923Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2005
- Primary completion
- Nov 2006
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of aliskiren in essential hypertension, sponsored by Novartis. Started Nov 2005; status: completed.
02
Drugs
aliskiren
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT00260923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00260923.